Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Invasive Mycoses

Last Updated: August 1, 2019; Last Reviewed: August 1, 2019

Invasive Mycoses (Cryptococcosis, Histoplasmosis, Coccidioidomycosis)
Member Financial Disclosure
Company Relationship
Ampel, Neil University of Arizona None N/A
Boulware, David University of Minnesota Appili Therapeutics Research Support
bioMerieux Speaker’s Bureau
Gilead Research Support
Hamill, Richard Baylor College of Medicine None N/A
Kauffman, Carol* University of Michigan and VA Ann Arbor Healthcare System Veterans Education and Research Association of Michigan Research Support
Miceli, Marisa University of Michigan Astellas Advisory Board, Consultant, Research Support
SCYNEXIS Consultant, Research Support
Pappas, Peter
University of Alabama at Birmingham Astellas Pharma Research Support
Cidara Therapeutics Advisory Board
Merck Research Support
SCYNEXIS Advisory Board, Research Support
Perfect, John Duke University Amplyx Pharmaceuticals Advisory Board, Research Support
Astellas Advisory Board, Research Support
Matinas BioPharma Holdings, Inc Advisory Board
Merck Advisory Board
Minnetronix Research Support
Mycovia Pharmaceuticals Advisory Board
Pfizer Research Support
Toyama Research Support
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines